Dergiler / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 3

TurkeyEffect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderatecoronavirus disease 2019IntroductionIn

Sayfa
184–190
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We found that there was a significant decrease in the QTD after the treatment in patients who were taking triple therapy including azithromycin.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The effects of treatment of coronavirus disease 2019 (COVID-19) with a triple combination composed of hydroxychloroquine, an an-tiviral, and an antibiotic on electrocardiography (ECG) parameters in patients with mild-to-moderate symptoms are not wholly understood.
📊
Temel Bulgular & Veri:We aimed to explore the changes in ECG parameters after treatment with triple combination therapy in patients with mild-to-moderate symptomatic COVID-19.Methods: This retrospective, single-center case series analyzed 91 patients with mild-to-moderate symptomatic COVID-19 at Ankara Gazi Mus-tafa Kemal State Hospital of Ankara City, Turkey, from April 1, 2020, to April 30, 2020.
💡
Sonuç & Katkı:We found that there was a significant decrease in the QTD after the treatment in patients who were taking triple therapy including azithromycin.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The effects of treatment of coronavirus disease 2019 (COVID-19) with a triple combination composed of hydroxychloroquine, an an-tiviral, and an antibiotic on electrocardiography (ECG) parameters in patients with mild-to-moderate symptoms are not wholly understood. We aimed to explore the changes in ECG parameters after treatment with triple combination therapy in patients with mild-to-moderate symptomatic COVID-19.Methods: This retrospective, single-center case series analyzed 91 patients with mild-to-moderate symptomatic COVID-19 at Ankara Gazi Mus-tafa Kemal State Hospital of Ankara City, Turkey, from April 1, 2020, to April 30, 2020. Forty-three patients were treated with hydroxychloroquine+oseltamivir+azithromycin (Group 1) and 48 patients were treated with hydroxychloroquine+oseltamivir+levofloxacin (Group 2). Heart rate, P wave duration, P wave dispersion, PR interval, QRS duration, corrected QT interval (QTc), QTc dispersion (QTD), delta QTc, Tp-e, Tp-e dispersion, and Tp-e/QTc ratio were all calculated from the baseline and posttreatment 12-lead ECG recordings.Results: The QTc, QRS duration, Tp-e, PR interval, and P wave duration were significantly increased after treatment (p 500 ms. Both Group 1 and Group 2 showed significant prolongation of the QTc interval (Group 1; p<0.001 vs. Group 2; p<0.001), QRS duration (Group 1; p=0.006 vs. Group 2; p=0.014), Tp-e (Group 1; p=0.036 vs. Group 2; p<0.001), and PR interval (Group 1; p=0.002 vs. Group2; p=0.05). The QTD was significantly decreased in Group 1 (p<0.001). None of the patients experienced any overt ventricular arrhythmia.Conclusion: To the best of our knowledge, this study is the first to investigate QT prolongation in a population of COVID-19 patients treated with triple combination therapy. We found that there was a significant decrease in the QTD after the treatment in patients who were taking triple therapy including azithromycin.

🔖

Bu Makaleye Atıf Yap

ILGIN, B. U., AKBULUT, İ. M., KIZILTUNÇ, E. (2021). TurkeyEffect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderatecoronavirus disease 2019IntroductionIn. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 3, 184–190. https://ajindex.com/articles/403150

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. References1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxy-chloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020
  2. 101663. 2. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimi-crob Agents 2020
  3. 105949. 3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020
  4. 192–206. 4. Kempa M, Gułaj M, Farkowski MM, Przybylski A, Sterliński M, Mit-kowski P. Electrotherapy and electrophysiology procedures during the coronavirus disease 2019 pandemic: an opinion of the Heart Rhythm Section of the Polish Cardiac Society (with an update). Kardiol Pol 2020
  5. Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label CO-VID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care 2020
  6. 215–21. 6. Bulut C, Kato Y. Epidemiology of COVID-19. Turk J Med Sci 2020
  7. 563–. Giudicessi JR, Noseworthy PA, Ackerman MJ. The QT Interval. Cir-culation 2019
  8. 2711–3. 8. Tse G, Yan BP. Traditional and novel electrocardiographic conduc-tion and repolarization markers of sudden cardiac death. Europace 2017
  9. 712–21. 9. Kors JA, Ritsema van Eck HJ, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008
  10. 575–80. 10. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment. J Am Coll Cardiol 2020
  11. 2623–4. 11. Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol 2020
  12. 948–51. 12. van den Broek MPH, Möhlmann JE, Abeln BGS, Liebregts M, van Dijk VF, van de Garde EMW. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J 2020
  13. 406–9. 13. Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT inter-val prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 2013
  14. 1719–26. 4. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, T